V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220018162 | 220009572 | 1.77 | 72 | Curative (C) | 2015-08-02 | 2016-01-01 | Capecitabine + Oxaliplatin 21day | N | N | 220036413 | SPIRIT TRIAL |
| 220018163 | 220009575 | null | 80 | Curative (C) | 2012-09-17 | 2013-05-16 | Spanish Maintenance (Months 4-24) | null | null | 220036427 | SORAFENIB |
| 220018164 | 220009576 | null | null | Curative (C) | 2016-03-09 | 2016-08-11 | DA-EPOCH-R | N | N | 220036432 | METHOTREXATE HIGH DOSE |
| 220018165 | 220009584 | 1.62 | 65.8 | Palliative (P) | 2016-12-29 | 2017-02-13 | CYTARABINE + ETOPOSIDE | 2 | N | 220036441 | IBRUTINIB |
| 220018167 | 220009586 | 1.95 | null | Palliative (P) | 2013-11-07 | 2014-07-22 | METHOTREXATE + PEGASPARGASE | 2 | N | 220036446 | CAPECITABINE + OXALIPLATIN |
| 220018168 | 220009586 | 1.68 | 73.1 | Disease modification (D) | 2017-09-15 | 2017-09-20 | Busulfan + Cyclophos Conditioning | N | N | 220036446 | BUSULPHAN + CYCLO |
| 220018170 | 220015081 | 0 | 54.1 | Palliative (P) | 2013-06-30 | 2013-07-01 | GCLAC | 02 | Y | 220036472 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 220018171 | 220015081 | null | 94.2 | Curative (C) | null | 2013-09-25 | Arsenic Triox + Tretinoin Ind W1-4 | N | null | 220036472 | VINORELBINE |
| 220018172 | 220009592 | 1.68 | 76 | Curative (C) | 2018-01-09 | 2018-03-31 | MACE | N | null | 220036485 | VINCRISTINE |
| 220018173 | 220018224 | 1.5 | 66.1 | Curative (C) | 2014-06-24 | 2014-12-09 | Capecitabine (21 day) + Irinotecan | N | N | 220036486 | CLOFARABINE + CYTSARABINE + IDARUBICIN |
| 220018174 | 220009594 | 1.56 | null | null | 2017-03-01 | 2017-03-14 | VINORELBINE | N | N | 220036524 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018175 | 220015084 | 1.75 | 100.5 | Palliative (P) | 2017-03-15 | 2017-09-01 | ALL UKALL2011 Maintenance A3 | 02 | N | 220036533 | CISPLATIN + PEMETREXED |
| 220018176 | 220009601 | 1.63 | -1 | Palliative (P) | 2014-12-15 | 2014-12-18 | PEMBROLIZUMAB | null | null | 220036542 | IVE |
| 220018178 | 220009606 | 1.7 | 108 | null | 2015-03-31 | 2018-03-27 | Bortezomib +/- Dexamethasone | N | N | 220036563 | CHOP R |
| 220018179 | 220009609 | null | null | Palliative (P) | 2014-01-15 | 2014-01-17 | DHAP | N | N | 220036575 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220018180 | 220009612 | 1.68 | null | Curative (C) | null | 2018-08-31 | Cladribine (subcut) 5 days | N | N | 220036586 | INTERFERON |
| 220018181 | 220009614 | null | null | Curative (C) | 2016-11-09 | 2016-11-11 | DTPACE | N | N | 220036590 | FIGARO TRIAL |
| 220018182 | 220009618 | 1.65 | 71.8 | Palliative (P) | 2014-04-14 | 2014-04-19 | Topotecan (intravenous) | N | N | 220036606 | INTERFERON |
| 220018183 | 220009624 | 1.85 | 63.6 | Adjuvant (A) | 2015-10-14 | 2015-11-25 | ATG + Busulfan + Fludarabine + Thiotepa | 2 | N | 220036614 | ARSENIC TRIOXIDE + ATRA |
| 220018184 | 220015093 | 2 | 97 | Palliative (P) | 2012-09-26 | 2012-10-10 | ALL Int Guide A/B/C Maint Ph V | 2 | N | 220036619 | ARSENIC TRIOXIDE + ATRA |
| 220018185 | 220009629 | 1.69 | null | Disease modification (D) | 2016-05-31 | 2017-08-16 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | 02 | N | 220036629 | EOX |
| 220018186 | 220009633 | null | 15.05 | Curative (C) | 2014-10-30 | 2014-10-30 | Alemtuzumab+Busulfan+CyclophosphMUD | null | N | 220036632 | CTD |
| 220018187 | 220009635 | null | null | Palliative (P) | 2015-12-17 | 2017-04-25 | FLUDARABINE | N | N | 220036633 | GEMCITABINE + PACLITAXEL |
| 220018188 | 220009638 | null | 101.699 | Adjuvant (A) | 2016-01-19 | 2016-01-25 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 220036640 | FEC |
| 220018189 | 220009640 | null | 51.1 | Palliative (P) | 2014-11-04 | 2014-11-10 | SPANISH MAINTENANCE | 2 | N | 220036641 | MIDAC |
| 220018190 | 220009648 | 1.62 | 66 | Curative (C) | 2017-04-28 | 2017-04-28 | LENALIDOMIDE | N | N | 220036653 | CYTARABINE + FLUDARABINE |
| 220018191 | 220015095 | null | null | Palliative (P) | 2013-12-20 | 2015-07-29 | Capecitabine | null | null | 220036654 | IVE |
| 220018193 | 220009655 | 1.68 | 120 | Disease modification (D) | 2018-02-09 | 2018-02-14 | BUSULFAN + FLUDARABINE | N | null | 220036675 | CYTARABINE IT + METHOTREXATE |
| 220018194 | 220009659 | null | 13.9 | Not known (9) | 2017-11-25 | 2017-11-25 | ALL UKALL2011 Maintenance A1 | null | N | 220036683 | CETUXIMAB |
| 220018195 | 220015102 | 1.72 | 88 | Curative (C) | 2018-06-23 | 2018-07-06 | VINCRISTINE | N | N | 220036725 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220018196 | 220009667 | 1.61 | null | Palliative (P) | 2015-08-12 | 2015-08-26 | Sunitinib | N | N | 220036733 | UKALL2011 |
| 220018197 | 220009668 | null | 69.1 | Palliative (P) | 2014-01-04 | 2014-01-16 | FIGARO TRIAL | 02 | Y | 220036733 | ARSENIC TRIOXIDE + ATRA |
| 220018199 | 220009673 | null | null | Palliative (P) | 2017-07-18 | 2018-06-26 | Cytarabine+Methotrexate Intrathecal | N | N | 220036750 | BUSULFAN + FLUDARABINE |
| 220018200 | 220009675 | 1.69 | 72.6 | null | 2013-05-02 | 2013-05-02 | CODOX M | N | N | 220036755 | GCLAC |
| 220018201 | 220009677 | 1.72 | 73 | Palliative (P) | null | 2018-09-12 | INTERFERON | 02 | N | 220036760 | MERCAPTOPURINE |
| 220018202 | 220009680 | null | null | null | 2013-07-27 | 2013-08-15 | ALL UKALL2011 Ind A Sht Dex (PAsp) | null | N | 220000653 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN |
| 220018203 | 220020004 | 1.57 | 56.5 | Adjuvant (A) | 2016-03-20 | 2016-04-17 | LENALIDOMIDE | N | N | 220002814 | CETUXIMAB + CISPLATIN + FU |
| 220018204 | 220009687 | 1.7 | 57 | Palliative (P) | 2016-05-21 | 2016-09-07 | CODOX M | 2 | N | 220003896 | BUSULPHAN + CYCLO |
| 220018205 | 220009689 | 1.67 | 78.4 | null | 2016-09-26 | 2016-10-06 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | N | 220004682 | CAPECITABINE + IRINOTECAN |
| 220018206 | 220009693 | null | 51.1 | Palliative (P) | null | 2017-05-09 | ALL UKALL2011 TRIAL | N | N | 220004682 | DACARBAZINE |
| 220018207 | 220015116 | null | null | Neo-adjuvant (N) | 2018-06-08 | 2018-06-13 | Alemtuzumab + Cyclophos TBI Allo | null | null | 220006910 | MELPHALAN |
| 220018208 | 220009696 | 1.62 | null | Disease modification (D) | 2015-07-03 | 2015-07-03 | Capecitabine | N | N | 220009544 | MACE |
| 220018209 | 220009698 | 1.65 | 61.7 | Palliative (P) | 2016-07-03 | 2016-07-09 | Cisplatin + Pemetrexed | 2 | N | 220011016 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220018210 | 220009700 | 1.62 | 116.3 | Palliative (P) | 2018-08-03 | 2018-08-08 | FIGARO TRIAL | N | null | 220014128 | EOX |
| 220018211 | 220009703 | -1 | null | Disease modification (D) | null | 2015-10-11 | Capecitabine | null | N | 220014221 | MELPHALAN |
| 220018212 | 220018243 | 1.64 | 75 | Disease modification (D) | 2018-05-13 | 2018-05-27 | Capecitabine | N | N | 220016525 | MITOXANTRONE + TRETINOIN |
| 220018213 | 220009708 | 1.66 | 127 | null | 2016-12-29 | 2016-12-31 | Lenalidomide 25mg (Cycle 1 to 25) | N | N | 220017507 | FIGARO TRIAL |
| 220018214 | 220015125 | 1.68 | null | Disease modification (D) | 2013-10-26 | 2014-03-30 | Methotrexate High Dose (3g/m2) | null | N | 220017673 | CYTARABINE + FLUDARABINE |
| 220018215 | 220009713 | 1.61 | 78.4 | Disease modification (D) | 2017-10-14 | 2018-04-01 | Irinotecan | N | N | 220018242 | CETUXIMAB + CISPLATIN + FU |
| 220018216 | 220009723 | null | 84.3 | Curative (C) | 2017-07-07 | 2017-12-25 | Alemtuzumab + Cyclophos TBI Allo | null | null | 220020424 | CYTARABINE IT + METHOTREXATE |